Research map: Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study

Back to the article

Papers in this map

  1. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis · April Wang Armstrong · 2020 · 2351 citations · Cited by this paper
  2. mRNA Vaccines for Influenza: Hope for a Universal Vaccine? · 2026 · Related
  3. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics · Alan Menter · 2019 · 971 citations · Cited by this paper
  4. Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability · 2025 · Related
  5. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations · Alexander Nast · 2020 · 420 citations · Cited by this paper
  6. Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential · 2025 · Related
  7. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update · Catherine Smith · 2020 · 260 citations · Cited by this paper
  8. Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics · 2026 · Related
  9. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) · Ulrich Mrowietz · 2015 · 210 citations · Cited by this paper
  10. Interleukin-23 Inhibitors in Inflammatory Bowel Disease · 2026 · Related
  11. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL · Kenneth B. Gordon · 2011 · 181 citations · Cited by this paper
  12. Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline · 2025 · Related
  13. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population · Jalpa A. Doshi · 2016 · 129 citations · Cited by this paper
  14. Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan’s C-CAT Registry · 2026 · Related
  15. Obesity-induced dysregulation of skin-resident PPARγ+ Treg cells promotes IL-17A-mediated psoriatic inflammation · Pulavendran Sivasami · 2023 · 116 citations · Cited by this paper
  16. Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review · 2025 · Related
  17. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta‐analysis · Ahmed I. Mourad · 2019 · 109 citations · Cited by this paper
  18. Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study · 2025 · Related
  19. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis · S.K. Mahil · 2020 · 96 citations · Cited by this paper
  20. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review · Marie Masson Regnault · 2022 · 85 citations · Cited by this paper
  21. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study · Hsien‐Yi Chiu · 2019 · 46 citations · Cited by this paper
  22. The association between obesity and efficacy of psoriasis therapies: An expert consensus panel · Joshua G. Burshtein · 2024 · 28 citations · Cited by this paper
  23. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation · Pedro Herranz · 2023 · 23 citations · Cited by this paper
  24. Saturated fatty acid-induced neutrophil extracellular traps contribute to exacerbation and biologic therapy resistance in obesity-related psoriasis · Yuting Xia · 2025 · 21 citations · Cited by this paper
  25. Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study · Selma Atalay · 2020 · 20 citations · Cited by this paper
  26. Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice · Semra Atalay · 2021 · 15 citations · Cited by this paper
  27. Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice · Selma Atalay · 2020 · 14 citations · Cited by this paper
  28. Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis · Hee Joo Kim · 2025 · 14 citations · Cited by this paper
  29. Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US · Benjamin N. Rome · 2025 · 14 citations · Cited by this paper
  30. Secukinumab: Review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR. · April Wang Armstrong · 2016 · 13 citations · Cited by this paper
  31. Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab · M Augustin · 2022 · 11 citations · Cited by this paper
  32. Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region · Annunziata Dattola · 2024 · 11 citations · Cited by this paper
  33. Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry · Robert R. McLean · 2023 · 10 citations · Cited by this paper
  34. Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study · Junchen Chen · 2025 · 10 citations · Cited by this paper
  35. Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a ‘perceived satisfaction’: a multicentric study · Ambra Di Altobrando · 2020 · 8 citations · Cited by this paper
  36. Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms · Annunziata Dattola · 2025 · 7 citations · Cited by this paper
  37. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study · Mia‐Louise Nielsen · 2023 · 7 citations · Cited by this paper
  38. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS) · Clarisse Marcombes · 2023 · 7 citations · Cited by this paper
  39. Development and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics · Shan Huang · 2024 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)